Biolife secures AU patent for cancer vaccine
Biolife Science has been granted an Australian patent covering cancer vaccine candidate HER-Vaxx.
The patent covers HER-Vaxx’s action against cancers associated with tumour antigen protein HER-2/neu. It grants Biolife Science intellectual property protection through to 2027.
HER-Vaxx is designed to stimulate HER-2 antibodies in early-stage cancer patients and has the potential to be a more potent alternative to Roche’s injectable antibody Herceptin. Nearly 20% of stomach cancers and 25-30% of breast cancers are HER-2 positive.
“With our intellectual property for HER-Vaxx now secured, we will have added confidence in its commercial viability moving forward,” Biolife Chariman-elect Dr Roger Aston said.
Biolife is currently conducting a backdoor ASX listing through a reverse takeover with ASX shell company Acuvax and an associated placement.
The company aims to raise up to $5 million through the placement to help fund phase II clinical trials for HER-Vaxx. Dr Aston and Paul Hooper have been selected to help lead the combined company.
“Biolife is eager to finalise its listing on the ASX and proceed with clinical trials of HER-Vaxx to further prove its effectiveness,” Dr Aston said.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
